Related Experiment Video
Updated: Jun 2, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Clinical experience with recombinant molecules for allergy vaccination
Oliver Cromwell1, Verena Niederberger, Friedrich Horak
1Allergopharma Joachim Ganzer KG, Hermann-Koerner-Strasse 52, 21465 Reinbek, Germany. oliver.cromwell@allergopharma.de
Abstract:
Numerous allergens have been cloned and produced by the use of recombinant DNA technology. In several cases recombinant variants with reduced IgE-reactivity have also been developed as candidates for allergen specific immunotherapy. Only very few of these proteins have as yet been tested in the clinic, and the major focus has been on birch and grass pollen, two of the most common causes of IgE-mediated allergic disease. This article serves to justify the rational for using recombinant products and reviews the progress that has been made to date with their clinical assessment.
Related Concept Videos
Cross-reactivity
Allergic Reactions
Vaccinations
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Allergic Reactions: Anaphylaxis
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.

